86528-43-0

Basic information

• Product Name: (1R*,2R*)-2-benzoylcyclohexane-1-carboxylic acid
• Synonyms: (1R*,2R*)-2-benzoylcyclohexane-1-carboxylic acid
• CAS NO: 86528-43-0
• Molecular Weight: 232.279
• Mol File: 86528-43-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (1R*,2R*)-2-benzoylcyclohexane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1R*,2R*)-2-benzoylcyclohexane-1-carboxylic acid(86528-43-0)
• EPA Substance Registry System: (1R*,2R*)-2-benzoylcyclohexane-1-carboxylic acid(86528-43-0)

Safety Data

• Hazardous Substances Data: 86528-43-0(Hazardous Substances Data)

Upstream product

• 85-42-7 1,2-Cyclohexanedicarboxylic acid-anhydride 
• 71-43-2 benzene 
• 100-58-3 phenylmagnesium bromide 
• 13149-00-3 1,2-cis-cyclohexanedicarboxylic anhydride 
• 86528-42-9 (1S*,2R*)-2-benzoylcyclohexane-1-carboxylic acid 
• 14166-21-3 (+/-)-trans-1,2-cyclohexanedicarboxylic anhydride 

Downstream Products

• 102462-17-9 (+/-)-2-(1-methyl-[4]piperidyl)-4-phenyl-(4ar,8at)-4a,5,6,7,8,8a-hexahydro-2H-phthalazin-1-one 
• 107264-24-4 C₂₇H₂₅NO₃ 
• 4992-42-1 (+/-)-trans-2-benzyl-cyclohexane-carboxylic acid-⁽¹⁾ 
• 3586-86-5 trans-1,2,3,4,4a,9a-hexahydro-9-(10H)-anthracenone 
• 113280-11-8 C₁₄H₁₅⁽²⁾HO₂ 
• 86528-47-4 (3α,3aβ,7aα)-hexahydro-3-phenyl-1(3H)-isobenzofuranone 
• 86528-45-2 trans 3,3a phenyl-3 cis 3a,7a hexahydro-3a,4,5,6,7,7a (3H) isobenzofurannone-1 
• 86528-48-5 (3α,3aβ,7aα)-hexahydro-3-phenyl-1(3H)-isobenzofuranone 
• 86528-46-3 (3α,3aβ,7aβ)-hexahydro-3-phenyl-1(3H)-isobenzofuranone 

Relevant articles and documents

Metal-Free Arylation-Lactonization Sequence of γ-Alkenoic Acids Using Anilines as Aryl Radical Precursors

The presence of salicylic acid (10 mol-%) and H2O (10 equiv.) significantly improves the arylation-lactonization sequence of γ-alkenoic acids with in situ formed diazonium salts (from bench stable anilines). The reaction is finished in less than 5 h without thermal or photochemical activation, giving access to a variety of γ,γ-disubstituted butyrolactones. The protocol is user-friendly and can be used at gram-scale or adapted to transform alkenols into phthalanes. Control experiments revealed that aryl radicals participate in the reaction and a plausible mechanism is proposed to include this and other mechanistic investigations, for the catalyzed and the background reaction.

THERAPEUTIC AGENT FOR DIABETES

A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4and R5are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6is a hydrogen atom or an amino-protecting group; R1is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.